Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2013-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/FPC.0b013e3283649b9aPMID 24018772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice

  2012cited by this paper
• Using a pharmacogenomic algorithm to guide the treatment of depression

  2012cited by this paper
• Pharmacogenomics of antidepressant treatment effects

  2011cited by this paper
• Serotonin transporter gene promotor polymorphism (5-HTTLPR) associations with number of psychotropic medication trials in a tertiary care outpatient psychiatric consultation practice.

  2011cited by this paper
• CYP2C19 variation and citalopram response

  2011cited by this paper
• Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice.

  2011cited by this paper
• Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials

  2011cited by this paper
• How Change Comes: Translating Biological Research into Care

  2011cited by this paper
• Reengineering Translational Science: The Time Is Right

  2011cited by this paper
• Facilitating clinical implementation of pharmacogenomics.

  2011cited by this paper
• Pharmacogenomic Considerations in Patients with Comorbid Medical and Psychiatric Illness

  2010cited by this paper
• Safety and Efficacy Pharmacogenomics in Pediatric Psychopharmacology

  2010cited by this paper
• Translational psychiatry: Bringing pharmacogenomic testing into clinical practice

  2010cited by this paper
• Personalized medicine for depression: can we match patients with treatments?

  2010cited by this paper
• The Clinical Use of Pharmacogenomic Testing in Treatment-Resistant Depression

  2010cited by this paper
• Improving the Prediction of Treatment Response in Depression: Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures

  2008cited by this paper
• STEP-BD and bipolar depression: What have we learned?

  2007cited by this paper
• Pharmacogenetic studies of antidepressant response: how far from the clinic?

  2007cited by this paper
• Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

  2006cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

  2006cited by this paper
• An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.

  2006cited by this paper
• Depression: management of depression in primary and secondary care

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cited by this paper
• Behavioral and antioxidant activity of a tosylbenz[g]indolamine derivative. A proposed better profile for a potential antipsychotic agent

  2004cited by this paper
• Gender difference in QTc prolongation of people with mental disorders

  2004cited by this paper
• Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

  2004cited by this paper
• Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

  2004cited by this paper
• The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation

  2004cited by this paper
• The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

  2003cited by this paper
• The PHQ-9: validity of a brief depression severity measure.

  2001cited by this paper
• A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.

  1985cited by this paper
• Development of a rating scale for primary depressive illness.

  1967cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Psychotropic pharmacogenetics in adult populations: From basic science to clinical trials and health economics – An evidence-based overview for decision makers

  2025cites this paper
• Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices

  2025cites this paper
• Comparative effectiveness of pharmacogenomic-guided versus unguided antidepressant treatment in major depressive disorder: new insights from subgroup and cumulative meta-analyses

  2025cites this paper
• PharmacoGENEtics in Youth Depression (GENE-YD) Study protocol: a pilot triple-blinded randomised controlled trial using pharmacogenetics to tailor antidepressant treatment in young Australians

  2025cites this paper
• Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression

  2025cites this paper
• An Assessment of Real-World Evidence and Other Sources Supporting Payer Coverage Decisions for Pharmacogenomic Testing in Psychiatry

  2025cites this paper
• Pharmacogenomics-guided treatment versus conventional treatment in patients with Schizophrenia: Evaluation of medication adherence and switching rate

  2025cites this paper
• Pharmacogenetic‑guided treatment in major depressive disorder

  2025cites this paper
• Pharmacogenomic Clinical Support Tools for the Treatment of Depression.

  2024cites this paper
• Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder

  2024cites this paper
• CYP2C19 Genetic Variants and Major Depressive Disorder: A Systematic Review

  2024cites this paper
• Pharmacogenomic Testing to Guide Treatment of Major Depressive Disorder: A Systematic Review

  2024cites this paper
• Exploring Youth-Perceived Barriers and Attitudes Towards the Clinical Use of Pharmacogenetic Testing to Optimise Antidepressant Pharmacotherapy

  2024cites this paper
• A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study

  2024cites this paper
• Unveiling the future: precision pharmacovigilance in the era of personalized medicine

  2024cites this paper
• Current status and prospects of nucleic acid mass spectrometry in clinical pharmacogenomics

  2024cites this paper
• Discovery of Methylenetetrahydrofolate Reductase (MTHFR) Deficiency in Individuals With Common Psychiatric Comorbidities: A Retrospective Case Review

  2024cites this paper
• Pharmacogenomic diversity in psychiatry: Challenges and Opportunities in Africa

  2024cites this paper
• Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: A systematic review and meta-analysis.

  2024cites this paper
• Precision Medicine in Antidepressants Treatment.

  2023cites this paper
• Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a meta-analysis of randomised controlled trials

  2023cites this paper
• Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder

  2023cites this paper
• Evaluating the prospective utility of pharmacogenetics reporting among Canadian Armed Forces personnel receiving pharmacotherapy: a preliminary assessment towards precision psychiatric care

  2023cites this paper
• Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review

  2023cites this paper
• Application of Pharmacogenomics Testing in a Community-based Facility

  2023cites this paper
• Toward Personalized Treatment of Depression: An Affordable Citalopram Test based on a Solid-Contact Potentiometric Electrode for at-Home Monitoring of the Antidepressant Dosage.

  2023cites this paper
• The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank

  2023cites this paper
• Pharmacogenomics and the Management of Mood Disorders—A Review

  2023influential citation
• Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders

  2023cites this paper
• Mental Health Prescribers’ Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region

  2023cites this paper
• A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical Resources.

  2023cites this paper
• Patient Attitudes Toward Pharmacogenetic Testing in Psychiatric Treatment

  2023cites this paper
• A randomized controlled trial of analogue pharmacogenomic testing feedback for psychotropic medications

  2022cites this paper
• Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials

  2022cites this paper
• Clinical utility of pharmacogenetics in a psychiatric and primary care population

  2022cites this paper
• Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder

  2022cites this paper
• Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression—Arguments for Preemptive Testing

  2022cites this paper
• Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

  2022cites this paper
• Genetic Testing for Diagnosis and Management of Behavioral Health Conditions

  2022cites this paper
• Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department

  2022cites this paper
• Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers

  2022cites this paper
• Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals

  2022cites this paper
• Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study

  2022cites this paper
• Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice

  2021cites this paper
• A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression

  2021cites this paper
• Laboratory medicine: The exemplar for value-based healthcare

  2021cites this paper
• The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review

  2021cites this paper
• Treatment-Resistant Depression Revisited: A Glimmer of Hope

  2021cites this paper
• Pharmacogenomics in Older Adults: An Integrative Review.

  2021cites this paper
• A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat

  2021cites this paper
• Using pharmacokinetics and pharmacogenetics to optimize psychiatric treatments: A systematic review.

  2021cites this paper
• Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)

  2021cites this paper
• Applying Pharmacogenomics in Drug Therapy of Neurologic and Psychiatric Disorders

  2021cites this paper
• Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.

  2021cites this paper
• Effect of pharmacogenomic testing on pharmacotherapy decision making in patients with symptoms of depression in an interprofessional primary care clinic.

  2021cites this paper
• Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.

  2021cites this paper
• What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?

  2021cites this paper
• Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling

  2021cites this paper
• The Utility of Pharmacogenetic-Guided Psychotropic Medication Selection for Pediatric Patients: A Retrospective Study

  2021cites this paper
• Perception and knowledge of pharmacogenetics among Brazilian psychiatrists.

  2021cites this paper
• Pharmacogenomics Guided Prescription Changes Improved Medication Effectiveness in Patients With Mental Health-Related Disability: A Retrospective Cohort Analyses

  2021cites this paper
• Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review

  2021cites this paper
• Effect of genetics clinical decision support tools on health-care providers’ decision making: a mixed-methods systematic review

  2021cites this paper
• An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis

  2021influential citation
• The clinical utility of pharmacogenetic testing in the treatment of bipolar disorder of Chinese patients.

  2020cites this paper
• The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis.

  2020cites this paper
• Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.

  2020cites this paper
• GeneSight Psychotropic Test

  2020influential citation
• Predicting treatment effects in unipolar depression: A meta-review.

  2020cites this paper
• Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia

  2020cites this paper
• Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?

  2020cites this paper
• Social Support Ameliorate Depressive Symptoms in Left-Behind Children in Rural China: A Cross-Sectional Study

  2020cites this paper
• Pharmacogenetic testing: 5 Questions

  2020cites this paper
• Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.

  2020cites this paper
• Considerations When Applying Pharmacogenomics to Your Practice.

  2020cites this paper
• Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times

  2020cites this paper
• Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population

  2020cites this paper
• Pharmacogenetics in Psychiatry: An Update on Clinical Usability

  2020cites this paper
• Genetic Testing for Diagnosis and Management of Mental Health Conditions

  2020cites this paper
• Attitudes on pharmacogenetic testing in psychiatric patients with treatment‐resistant depression

  2020cites this paper
• An Effective Method to Facilitate Personalized and Precise Medicine for Schizophrenia Treatment Based on Pharmacogenomics

  2020cites this paper
• Can precision medicine advance psychiatry?

  2020cites this paper
• Open-label pilot study of psychiatric pharmacogenetic testing in an adult psychiatric inpatient population

  2020cites this paper
• Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective.

  2020cites this paper
• Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry

  2019cites this paper
• To be submitted to Expert Review of Molecular Diagnostics Blood Biomarkers and Treatment response in Major Depression

  2019cites this paper
• Early adoption of pharmacogenetic testing for veterans prescribed psychotropic medications.

  2019cites this paper
• Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression

  2019cites this paper
• Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study

  2019cites this paper
• Economic Evaluation of Pharmacogenomic Testing

  2019cites this paper
• Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study

  2019cites this paper
• Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?

  2019cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients

  2019cites this paper
• Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications

  2019cites this paper
• CEOR_A_224277 779..787

  2019cites this paper
• Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications

  2019cites this paper
• Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.

  2019influential citation
• Integrating Genomics into Psychiatric Practice: Ethical and Legal Challenges for Clinicians

  2019cites this paper
• Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care - The reality of treatment resistant-based therapies.

  2019cites this paper